2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists capable of inducing receptor endocytosis

Shukla, Lena and Ajram, Laura A. and Begg, Malcolm and Evans, Brian and Graves, Rebecca H. and Hodgson, Simon T. and Lynn, Sean M. and Miah, Afjal H. and Percy, Jonathan M. and Procopiou, Panayiotis A. and Richards, Stephen A. and Slack, Robert J. (2016) 2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists capable of inducing receptor endocytosis. European Journal of Medicinal Chemistry, 115. pp. 14-25. ISSN 0223-5234

[img]
Preview
Text (Shukla-etal-EJMC2016-2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine-potent-CCR4)
Shukla_etal_EJMC2016_2_8_Diazaspiro_4.5_decan_8_yl_pyrimidin_4_amine_potent_CCR4.pdf
Accepted Author Manuscript
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo

Download (994kB)| Preview
    [img] Text (EJMC910)
    EJMC910.docx
    Accepted Author Manuscript
    License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo

    Download (508kB)

      Abstract

      A number of potent 2,8-diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine CCR4 antagonists binding to the extracellular allosteric site were synthesised. (R)-N-(2,4-Dichlorobenzyl)-2-(2-(pyrrolidin-2-ylmethyl)-2,8-diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine (R)-(18a) has high affinity in both the [125I]-TARC binding assay with a pKi of 8.8, and the [35S]-GTPγS functional assay with a pIC50 of 8.1, and high activity in the human whole blood actin polymerisation assay (pA2 = 6.7). The most potent antagonists were also investigated for their ability to induce endocytosis of CCR4 and were found to internalise about 60% of the cell surface receptors, a property which is not commonly shared by small molecule antagonists of chemokine receptors.